Search

Your search keyword '"Centre Eugène Marquis (CRLCC)"' showing total 2 results
Start Over Author "Centre Eugène Marquis (CRLCC)" Publisher elsevier
2 results on '"Centre Eugène Marquis (CRLCC)"'

1. Radiothérapie guidée par l'image et adaptative. [Image-guided and adaptive radiotherapy.]

Author

Centre Eugène Marquis ; CRLCC Eugène Marquis, IMPACT ; Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1 - Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM, IMPACT ; Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1, Impact ; Centre Eugène Marquis ; CRLCC Eugène Marquis - CRLCC Eugène Marquis - Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1, Louvel, Guillaume, Cazoulat, Guillaume, Chajon, Enrique, Le Maitre, Amandine, Simon, Antoine, Henry, Olivier, Bensadoun, R. J., De Crevoisier, Renaud, Centre Eugène Marquis ; CRLCC Eugène Marquis, IMPACT ; Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1 - Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM, IMPACT ; Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1, Impact ; Centre Eugène Marquis ; CRLCC Eugène Marquis - CRLCC Eugène Marquis - Laboratoire Traitement du Signal et de l'Image (LTSI) ; INSERM - Université de Rennes 1 - INSERM - Université de Rennes 1, Louvel, Guillaume, Cazoulat, Guillaume, Chajon, Enrique, Le Maitre, Amandine, Simon, Antoine, Henry, Olivier, Bensadoun, R. J., and De Crevoisier, Renaud

Abstract

International audience, Image-guided radiotherapy (IGRT) aims to take into account anatomical variations occurring during irradiation by visualization of anatomical structures. It may consist of a rigid registration of the tumour by moving the patient, in case of prostatic irradiation for example. IGRT associated with intensity-modulated radiotherapy (IMRT) is strongly recommended when high-dose is delivered in the prostate, where it seems to reduce rectal and bladder toxicity. In case of significant anatomical deformations, as in head and neck tumours (tumour shrinking and decrease in volume of the salivary glands), replanning appears to be necessary, corresponding to the adaptive radiotherapy. This should ideally be "monitored" and possibly triggered based on a calculation of cumulative dose, session after session, compared to the initial planning dose, corresponding to the concept of dose-guided adaptive radiotherapy. The creation of "planning libraries" based on predictable organ positions (as in cervical cancer) is another way of adaptive radiotherapy. All of these strategies still appear very complex and expensive and therefore require stringent validation before being routinely applied.

2. Review of clinical applications of radiation-enhancing nanoparticles

Author

E. Chajon, Valentin Calugaru, N. Scher, C. Le Tourneau, Sylvie Bonvalot, Juliette Thariat, C. Verry, Institut Curie [Paris], Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie - Saint Cloud (ICSC), Centre Eugène Marquis (CRLCC), CHU Grenoble, Synchrotron Radiation for Biomedicine = Rayonnement SynchroTROn pour la Recherche BiomédicalE (STROBE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Radiothérapie [Centre François Baclesse], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), CCSD, Accord Elsevier, and MINES ParisTech - École nationale supérieure des mines de Paris

Subjects
0106 biological sciences, Oncology, medicine.medical_specialty, Gadolinium, medicine.medical_treatment, [SDV]Life Sciences [q-bio], lcsh:Biotechnology, chemistry.chemical_element, Review Article, 01 natural sciences, Applied Microbiology and Biotechnology, 03 medical and health sciences, 010608 biotechnology, Internal medicine, lcsh:TP248.13-248.65, medicine, 030304 developmental biology, Radiothérapie, Cancer, Cervical cancer, 0303 health sciences, Radiotherapy, business.industry, Nanoparticules, medicine.disease, Head and neck squamous-cell carcinoma, 3. Good health, Clinical trial, Radiation therapy, [SDV] Life Sciences [q-bio], chemistry, Nanoparticles, Sarcoma, Liver cancer, business, Biotechnology
Abstract

Highlights • Inorganic nanoparticles activated by radiotherapy (RT) increase dose deposition within cancer cells compared to RT alone. • Recently, clinical evidence of the radiation-enhancing effects of NP has emerged. • Two radio-enhancement NP are currently under investigation in clinical trials: hafnium oxide NP and gadolinium-based NP. • So far, 229 patients have been treated with NP and RT for soft tissue sarcoma, head and neck cancers or liver cancer. • Intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma., Purpose Clinical evidence of the radiation-enhancing effects of nanoparticles has emerged. Materials and methods We searched the literature in English and French on PubMed up to October 2019. The search term was “nanoparticle” AND “radiotherapy”, yielding 1270 results. Results The two main NP used in clinical trials were hafnium oxide and gadolinium involving a total of 229 patients. Hafnium oxide NP were used in three phase 1/2 trials on sarcoma, head and neck squamous cell carcinoma or liver cancer and one phase 2/3 trial. There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer. Conclusion So far, intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results